SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001610618-24-000054
Filing Date
2024-04-29
Accepted
2024-04-29 16:57:28
Documents
16
Period of Report
2024-04-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CIDARA THERAPEUTICS, INC. FORM 8-K/A cdtx-20240423.htm   iXBRL 8-K/A 40383
2 ASSET PURCHASE AGREEMENT exhibit212024-04x29.htm EX-2.1 727172
3 ASSIGNMENT AND NOVATION AGREEMENT exhibit222024-04x29.htm EX-2.2 87769
4 1ST AMENDMENT TO MELINTA LICENSE AGREEMENT exhibit232024-04x29.htm EX-2.3 32475
  Complete submission text file 0001610618-24-000054.txt   1167925

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20240423.xsd EX-101.SCH 1899
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdtx-20240423_lab.xml EX-101.LAB 23661
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdtx-20240423_pre.xml EX-101.PRE 13571
19 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20240423_htm.xml XML 8351
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36912 | Film No.: 24892217
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)